Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.

ABSTRACT:

Importance

Diffuse malignant peritoneal mesothelioma (DMPM) represents a rare and clinically distinct entity among malignant mesotheliomas. Pembrolizumab has activity in diffuse pleural mesothelioma but limited data are available for DMPM; thus, DMPM-specific outcome data are needed.

Objective

To evaluate outcomes after the initiation of pembrolizumab monotherapy in the treatment of adults with DMPM.

Design, setting, and participants

This retrospective cohort study was conducted in 2 tertiary care academic cancer centers (University of Pennsylvania Hospital Abramson Cancer Center and Memorial Sloan Kettering Cancer Center). All patients with DMPM treated between January 1, 2015, and September 1, 2019, were retrospectively identified and followed until January 1, 2021.

SUBMITTER: Marmarelis ME 

PROVIDER: S-EPMC10942662 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature